Innovative Pain Relief Theranica’s flagship Nerivio REN wearable offers a drug-free, FDA-cleared solution for migraine treatment, appealing to healthcare providers and patients seeking effective, low-side-effect therapies especially for adolescents and veterans.

Expanding Pediatric Focus The company's recent spotlight at the 2025 CNS Annual Meeting on pediatric migraine care indicates a growing emphasis on targeting younger demographics, creating opportunities to collaborate with pediatric neurologists and clinics.

Award-Winning Technology Recognition like the 2021 MedTech Breakthrough Award enhances the company's credibility and opens doors to partners in the medical device and pain management markets seeking innovative solutions.

Market Penetration Potential With over 650,000 treatments conducted in the US and a presence in both acute and preventive care, Theranica is well-positioned to expand sales efforts to healthcare institutions and insurance providers seeking effective migraine management tools.

Financial Growth Opportunity Generating between 50 to 100 million dollars in revenue with a relatively lean team, Theranica presents a scalable opportunity for partners interested in advancing neuromodulation therapies and boosting product adoption in neuroscience and pain clinics.